Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Investor Presentation (February 2023)
21 slides from Pyc Therapeutics's investor presentation, Feb 17, 2023
Slide 1: Life-changing science: Q1 Investor Update
For personal use only Life-changing science Q1 Investor Update February 2023
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. A
Slide 3: Discussion topics – Q1 investor update
Discussion topics – Q1 investor update For personal use only • An introduction to PYC • An update on the global life sciences environment • The RNA therapeutics backdrop within the industry • Pipeline review • PYC’s progress through Q4 2022 and YTD 2023 • Forward view for PYC in 2023 • Q&A PYC THERA
Slide 4: Introduction to PYC
For personal use only Life-changing science Introduction to PYC
Slide 5: PYC discovers and develops RNA therapies for patients with genetic diseases
For personal use only PYC discovers and develops RNA therapies to change the lives of patients with genetic diseases PYC THERAPEUTICS 5
Slide 6: PYC's RNA delivery platform overcomes the primary challenge for precision therapies
PYC’s RNA delivery platform overcomes the primary challenge for precision therapies – ensuring enough drug reaches its target For personal use only PYC combines existing RNA drug design PYC’s drug delivery platform is used to assist technology with its proprietary drug delivery the RNA drug reach it
Slide 7: Strategy anchored on four critical features
PYC is creating therapies for patients through a strategy anchored on four critical features For personal use only A HIGHER PROBABILITY A FASTER PATH LIKELY RAPID UPTAKE ORPHAN DRUG OF SUCCESS TO MARKET IN MARKET PRICING PYC focuses on The potential for First-in-class drugs in Median list price of m
Slide 8: Focus on genetic validation of selected targets
The key to understanding PYC is the Company’s focus on genetic validation of the targets it has selected For personal use only A HIGHER PROBABILITY OF SUCCESS “When you’re following Nature’s lamp PYC focuses on posts… Much higher probability of success” monogenic indications. Atlas Ventures 2022 yea
Slide 9: Progressing first-in-class drugs into the clinic within 24 months
PYC is looking to progress 3 first-in-class and disease-modifying drugs into the clinic within 24 months For personal use only PYC IS HERE Scale into multiple clinical 3 safety and efficacy read-outs Evolution to a clinical- 2 stage multi-asset company Objectives • Establish human safety of PYC’s pl
Slide 10: Industry trends
For personal use only Life-changing science Industry trends
Slide 11: PYC is in the right place at the right time
PYC is in the right place at the right time For personal use only Right Place “Many examples here from monogenic diseases, where we know this gene is the gene, and we know this is the problem… And now we know exactly what we can do. So that’s a very different paradigm” ¹ Right Time Novartis is focus
Slide 12: Program deep-dives (progress and anticipated milestones)
For personal use only Life-changing science Program deep-dives (progress and anticipated milestones)
Slide 13: RP11 – progress and expected milestones
RP11 – progress and expected milestones For personal use only Current progress Progress expected in 2023 Organ Program Target Discovery Pre-clinical IND enabling Clinical Trials Marketed VP-001* PRPF31 Retinitis Pigmentosa Type 11 PYC-001 OPA1 Autosomal Dominant Optic Atrophy PYC-002 SHANK3 Phelan-M
Slide 14: VP-001 set to become first disease-modifying drug for RP11
VP-001 is set to become the first investigational drug with disease-modifying potential for patients with RP11 For personal use only 5,000 – 10,000 patients USD $150,000 p.a. Estimated addressable RP11 patient Median list price of orphan drugs (per patient2) population in the western world1 Patients
Slide 15: PYC set to generate human safety and efficacy data for VP-001
PYC is set to generate human safety and efficacy data for VP-001¹ For personal use only Phase 1/2 Human Trial Pivotal Trial Part 1 Part 2 • Single Ascending Dose Study • Multiple dose expansion • Trial design will be informed • 3+3+3 dose escalation in study by: RP11 patients • 3 groups of 10 patien
Slide 16: ADOA – progress and expected milestones
ADOA – progress and expected milestones For personal use only Current progress Progress expected in 2023 Organ Program Target Discovery Pre-clinical IND enabling Clinical Trials Marketed VP-001* PRPF31 Retinitis Pigmentosa Type 11 PYC-001 OPA1 Autosomal Dominant Optic Atrophy PYC-002 SHANK3 Phelan-M
Slide 17: PYC-001 'mini-eyes' results anticipated in Q2
Results from the testing of PYC-001 in ‘mini-eyes’ are anticipated in Q2 For personal use only “The explosive developing field of induced pluripotent stem cells (iPSCs) reprogrammed from primary patient-derived cell cultures provides the remarkable and unique opportunity to obtain specialized termin
Slide 18: PMS – progress and expected milestones
PMS – progress and expected milestones For personal use only Current progress Progress expected in 2023 Organ Program Target Discovery Pre-clinical IND enabling Clinical Trials Marketed VP-001* PRPF31 Retinitis Pigmentosa Type 11 PYC-001 OPA1 Autosomal Dominant Optic Atrophy PYC-002 SHANK3 Phelan-Mc
Slide 19: Platform/discovery – progress and expected milestones
Platform/discovery – progress and expected milestones For personal use only Current progress Progress expected in 2023 Organ Program Target Discovery Pre-clinical IND enabling Clinical Trials Marketed VP-001* PRPF31 Retinitis Pigmentosa Type 11 PYC-001 OPA1 Autosomal Dominant Optic Atrophy PYC-002 S
Slide 20: PYC's technology is rapidly scalable
PYC’s technology is rapidly scalable – supporting the Company’s ambition of progressing a new drug into the clinic every year For personal use only “Once the nucleic acid chemistry and the delivery method are established, the production of RNA-based drugs for a new target can be achieved in a relati
Slide 21: Q&A
For personal use only Life-changing science Q&A
PYC Therapeutics — Investor Presentation (February 2023) on 6ix